Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that the abstract titled “Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma,” to be presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting is now available at http://www.immunotherapyofcancer.org/content/2/S3/P120. The poster concludes that certain studies “support the induction of increased tumor-specific immunity after co-inhibitory blockade in combination with IL PV-10 therapy.”
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
